ArticleBMC microbiology2025
Potential interactions between vancomycin and meropenem in culture-negative periprosthetic joint infection: an in vitro study.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- DVIA technique for acute periprosthetic joint infection: a surgical technique and case series.Arthroplasty (London, England) · 2026Article
- [Effects of high-concentration of vancomycin and meropenem on viability and osteogenic differentiation of rat bone marrow mesenchymal stem cells].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Article
- One-stage exchange arthroplasty for periprosthetic joint infection following total knee arthroplasty with sinus tract: a mid-to short-term follow-up study.BMC musculoskeletal disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCulture-negative periprosthetic joint infections (CN-PJIs) represent a critical subtype of PJI, and their high prevalence poses substantial challenges for treatment. CN-PJI is commonly managed utilizing antibiotic combinations, however, the interactions between these antibiotics have not been investigated. The aim of study was to investigate the synergistic and antagonistic effects of vancomycin (VAN) and meropenem (MEM), in an in vitro model of CN-PJI.
methodsMinimum Inhibitory Concentration (MIC), Minimum Bactericidal Concentration (MBC), Minimum Biofilm Inhibitory Concentration (MBIC), and Minimum Biofilm Eradication Concentration (MBEC) were determined for VAN and MEM. Fractional Inhibitory Concentration (FIC) and Fractional Biofilm Eradication Concentration (FBEC) indices were calculated to assess the synergistic or antagonistic effects of VAN in combination with MEM on Staphylococcus aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis), and Escherichia coli (E. coli) incubated alone or in combination.
resultsIn the planktonic bacterial phase, MEM showed higher activity than VAN. Resistance increased when the bacteria were cultured together. The combination of VAN and MEM exhibited an indifferent effect against individual Staphylococci but an antagonistic effect against polymicrobial cultures. In biofilm, MEM demonstrated better antibiofilm activity than VAN, especially against E. coli biofilms. The combination of VAN and MEM showed an indifferent effect against E. coli and S. epidermidis-E. coli biofilms, but an antagonistic effect against S. aureus, S. epidermidis, S. aureus-S. epidermidis, and S. aureus-E. coli biofilms.
conclusionThis study provides valuable insights into the effectiveness of VAN and MEM combinations in treating CN-PJIs, highlighting the need for careful consideration when selecting antibiotic treatments for these infections. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.